Core Insights - TNX-4800 is a long-acting monoclonal antibody in development as a single-dose prophylactic for Lyme disease, demonstrating safety and pharmacokinetics supportive of approximately four months of protection [1][2][3] Phase 1 Study Results - The Phase 1 study evaluated the safety and tolerability of TNX-4800 in 44 healthy subjects aged 19-65, with 41 completing the study [4][10] - No significant safety signals were observed, with most adverse events being mild or moderate [5][12] - Peak serum concentration increased by approximately 25-fold for a 20-times increase in dose, with serum TNX-4800 measurable at two days and remaining quantifiable for over 200 days in 80% of subjects at the lowest dose [5][12] Mechanism and Advantages - TNX-4800 targets the outer surface protein A (OspA) of Borrelia burgdorferi, which causes 99.9% of Lyme disease cases in the U.S. [2][9] - The antibody provides passive immunity by directly supplying neutralizing antibodies, bypassing the need for a vaccine to induce the immune system [4][9] - Unlike existing vaccines that require complex immunization schedules and take over six months to provide protection, TNX-4800 offers immunity within two days with a single subcutaneous dose [3][9] Future Study Plans - The company plans to initiate a randomized, double-blind, placebo-controlled adaptive Phase 2 field study in the first half of 2027, pending FDA clearance [1][6] - The primary endpoint will be the prevention of Lyme disease at four months, with a key secondary endpoint at six months [6][11] Product Development and Background - TNX-4800 was in-licensed from UMass Chan Medical School in 2025 and is designed to maintain protective antibody levels for approximately four months [2][9] - The company expects to have GMP investigational product available for clinical testing in early 2027 [7]

Core Insights - Tonix Pharmaceuticals announced the presentation of Phase 1 data on TNX-4800, a long-acting human monoclonal antibody for the seasonal prevention of Lyme disease, at the World Vaccine Congress Washington 2026 [1][3] Group 1: TNX-4800 Overview - TNX-4800 targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacterium responsible for Lyme disease, and has shown 95% effectiveness in preventing infection in animal studies [4][6] - The antibody is designed to provide immunity within two days of administration and maintain protective antibody levels throughout the tick season, offering a pre-exposure prophylaxis without relying on the recipient's immune system [4][6] - The company expects to have GMP investigational product available for clinical testing in early 2027, with a field study anticipated to begin enrollment in the first half of 2027 [5] Group 2: TNX-801 Overview - TNX-801 is a live attenuated horsepox virus vaccine candidate aimed at preventing smallpox and mpox, expected to enter Phase 1 studies in 2027 pending FDA clearance [8] Group 3: Phase 1 Study Details - The Phase 1 study of TNX-4800 involved 44 subjects, with 41 completing the study, assessing safety, tolerability, pharmacokinetics, and immunogenicity [6] - Drug exposure increased approximately 25 times for a 20 times increase in dose, with serum TNX-4800 measurable within 24 hours and remaining quantifiable for over 200 days in 80% of volunteers at the lowest dose [6] - The mean half-life of TNX-4800 ranged from 62-69 days, with most adverse events being mild or moderate, indicating that TNX-4800 is generally safe and well tolerated [6] Group 4: Lyme Disease Context - Lyme disease is the most common vector-borne infection in the U.S., caused by Borrelia burgdorferi, with increasing incidence due to climate changes affecting tick habitats [7] - Typical symptoms include fever, headache, fatigue, and a characteristic skin rash, with untreated infections potentially spreading to joints, heart, and nervous system [7]

Company Overview - Tonix Pharmaceuticals Holding Corp. is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments addressing high unmet medical needs [2] - The company’s marketed products include TONMYA, the first new treatment for fibromyalgia in over 15 years, and acute migraine products Zembrace Symtouch and Tosymra [2] - Tonix is advancing a pipeline that includes investigational drugs for major depressive disorder, acute stress disorder, Prader-Willi syndrome, Lyme disease prophylaxis, and kidney transplant rejection [2] Upcoming Presentation - Seth Lederman, MD, the CEO of Tonix, will present at BIO-Europe Spring 2026 on March 24, 2026, from 1:30 to 1:45 p.m. WET in Lisbon, Portugal [1][2] - The presentation will take place in Presentation Theatre A [2] Product Development - TONMYA is currently being evaluated in Phase 2 clinical trials for its potential in treating major depressive disorder and acute stress disorder [2] - TNX-2900 is Phase 2 ready for treating Prader-Willi syndrome, a rare disease [2] - The immunology pipeline includes monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection [2]

Tonix Pharmaceuticals Conference Call Summary Company Overview - **Company**: Tonix Pharmaceuticals (NasdaqCM: TNXP) - **Focus**: Development and commercialization of pharmaceutical products, particularly for fibromyalgia and Lyme disease Key Points on Fibromyalgia Treatment - **Product Launch**: Tonmya, a sublingual cyclobenzaprine, launched on November 17, 2025, is the first new treatment for fibromyalgia in over 15 years [4][5] - **Commercial Transition**: The company has transitioned to a commercial stage over the past two and a half years, acquiring two migraine products to establish its commercial infrastructure [4][5][6] - **Sales Force**: Approximately 90 representatives are actively promoting Tonmya, utilizing omnichannel strategies to connect with healthcare providers [5][6] - **Physician Feedback**: Early anecdotal feedback from physicians indicates positive patient results, with no significant negative surprises reported [9][10] - **Prescriber Demographics**: Prescribers include 30% rheumatologists, 30% primary care physicians, and others from pain management and neurology specialties [10][11] - **Market Positioning**: Tonmya is being positioned as a first-line monotherapy for fibromyalgia, with a focus on patients who may cycle through various treatments due to limited benefits of existing drugs [13][14] Access and Reimbursement - **Payer Coverage**: The company is actively engaging with payers to secure coverage, emphasizing the importance of maintaining reasonable rebates to ensure profitability [20][21] - **Market Dynamics**: The three major payers control over 90% of the market, and the company is hopeful that the value proposition of a non-opioid analgesic will be recognized [22] Key Metrics for Launch Success - **Metrics Monitored**: Total prescriptions, new prescriptions, and the number of unique prescribers are key metrics being tracked to assess the launch's success [23][24] - **Growth Pattern**: The company describes its growth as linear rather than exponential at this stage, with ongoing efforts to increase prescription rates [24][25] Lyme Disease Program - **Product Overview**: The Lyme disease program involves a long-acting monoclonal antibody designed to prevent Lyme disease, with an expected duration of protection from spring to fall [27][28] - **Target**: The antibody targets the OspA protein on Borrelia, the bacteria causing Lyme disease, and is distinct from vaccines as it provides passive immunity [30][31] - **Market Demand**: An estimated 70 million Americans live in Lyme endemic areas, with 500,000 cases reported annually, indicating a significant potential demand for preventative therapy [33] Investor Insights - **Underestimated Aspects**: Investors may not fully appreciate the significance of the launch of Tonmya and the potential of the Lyme disease program, as well as the company's financial position with $208 million in cash and a one-year runway for launch efforts [34][35] Conclusion - **Future Outlook**: The company is optimistic about its growth trajectory and the potential impact of its products on underserved patient populations, particularly in fibromyalgia and Lyme disease [34][35]

Core Viewpoint - Tonix Pharmaceuticals has launched TONMYA, the first FDA-approved treatment for fibromyalgia in over 15 years, demonstrating rapid pain relief and a favorable benefit-risk profile in clinical studies [1][2]. Group 1: Product Overview - TONMYA (cyclobenzaprine HCl sublingual tablets) was approved by the FDA on August 15, 2025, for the treatment of fibromyalgia in adults [9]. - The formulation allows for rapid transmucosal absorption and reduces the production of a long half-life active metabolite, norcyclobenzaprine, due to bypassing first-pass hepatic metabolism [9]. - TONMYA is also being investigated for other conditions, including acute stress reaction, acute stress disorder, and major depressive disorder [9]. Group 2: Clinical Study Results - In the RESILIENT trial, TONMYA showed significant pain reduction as early as Day 2, with a statistically significant change in weekly average daily numeric rating scale (NRS) pain scores (p<0.001) [3]. - The primary endpoint was met with a least-squares mean treatment difference of -0.65, and all key secondary endpoints were statistically significant in favor of TONMYA [3]. - A pooled analysis of the RELIEF and RESILIENT studies indicated that the number needed to treat (NNT) for a clinically meaningful ≥30% pain reduction was 7, while the number needed to harm (NNH) for discontinuation due to adverse events was 26, resulting in a likelihood to be helped or harmed (LHH) of 3.7 [5]. Group 3: Safety and Tolerability - TONMYA was generally well tolerated, with a discontinuation rate due to adverse events of 6.1% compared to 3.5% for placebo [4]. - The most common treatment-emergent adverse events included oral cavity reactions, such as oral hypoesthesia (23.8%) and abnormal product taste (11.7%), which were typically mild and transient [4][6]. - Safety data were consistent with the known profile of TONMYA, with no new or unexpected safety signals reported [6]. Group 4: Market Context - Approximately 10 million adults in the U.S. suffer from fibromyalgia, with a significant unmet medical need for effective treatments [2][8]. - Physicians and patients have expressed dissatisfaction with currently marketed products, highlighting the potential market opportunity for TONMYA [8].

Core Insights - TONMYA (cyclobenzaprine HCl sublingual tablets) is the first new FDA-approved treatment for fibromyalgia in adults in over 15 years, launched commercially in the U.S. in November 2025 [1] - The formulation is designed for rapid transmucosal absorption, bypassing first-pass liver metabolism, which enhances the durability of analgesic response compared to traditional oral cyclobenzaprine [1][2] - Clinical studies indicate that TONMYA provides a durable analgesic benefit and is generally well tolerated among fibromyalgia patients [2][5] Company Overview - Tonix Pharmaceuticals Holding Corp. is a fully integrated biotechnology company focused on central nervous system (CNS) and immunology treatments, with TONMYA as its flagship product [9] - The company is also developing other treatments, including those for major depressive disorder and acute stress disorder, leveraging its proprietary formulations [9] Product Details - TONMYA utilizes a patented sublingual formulation that enhances drug exposure during sleep while minimizing side effects associated with the active metabolite norcyclobenzaprine [8] - The product is indicated for the treatment of fibromyalgia in adults and is expected to have U.S. market exclusivity until 2034/2035 due to multiple patents [8] Clinical Study Findings - Study 1 demonstrated that the potassium phosphate dibasic formulation of TONMYA achieved a 154% relative bioavailability compared to oral immediate-release cyclobenzaprine, with a significantly shorter absorption lag [3] - Study 2 confirmed the absence of food effects on pharmacokinetic parameters and characterized the active metabolite's elimination half-life as approximately 60 hours [4] Market Context - Fibromyalgia affects an estimated 6-12 million adults in the U.S., predominantly women, and is characterized by chronic pain and other debilitating symptoms [7] - There is a noted dissatisfaction with currently marketed products for fibromyalgia, highlighting the potential market opportunity for TONMYA [7]

Tonix Pharmaceuticals FY Conference Summary Company Overview - **Company Name**: Tonix Pharmaceuticals (NasdaqCM: TNXP) - **Focus**: Fully integrated pharmaceutical company with a focus on the launch of Tonmya, a treatment for fibromyalgia, and other therapeutic areas including migraine treatments [2][3] Key Products and Developments - **Tonmya**: - A sublingual cyclobenzaprine tablet approved for fibromyalgia treatment, launched on November 17, 2025 [4][6] - Targets disturbed sleep quality in fibromyalgia, addressing a high unmet need in a market with approximately 10 million adults affected in the U.S. [4][11] - Reported $1.4 million in net sales since launch [6] - Unique mechanism and first-in-class designation, with a focus on the 5% of prescribers who account for 70% of prescriptions [6][18] - **Migraine Treatments**: - Acquired two migraine products, Tosymra (sumatriptan nasal spray) and Zembrace (sumatriptan injection), but are gradually decreasing promotion of these products [19] Market Dynamics - **Fibromyalgia Market**: - High dissatisfaction with existing treatments, with only 3 million out of 10 million diagnosed and treated [12][13] - Potential for increased diagnosis among long COVID patients, with estimates suggesting 20-30 million may be affected [12] - Tonmya's pricing set at $1,860 per month for long-term use [18] - **Challenges and Opportunities**: - Need for education among prescribers about fibromyalgia and Tonmya [17][18] - Existing drugs for fibromyalgia are often misprescribed, with a significant reliance on opioids, which are not indicated for this condition [15][16] Clinical Pipeline - **Upcoming Studies**: - Lyme prophylactic program with promising phase one data, targeting a long-acting monoclonal antibody [27][28] - Studies for major depressive disorder and acute stress disorder funded by the U.S. Department of Defense [30] - Phase 2 study for kidney transplant treatment [31][32] Financial Position - **Financial Health**: - Ended the previous year with $208 million in cash and no debt, indicating a strong balance sheet [3] Conclusion - Tonix Pharmaceuticals is positioned for growth with a strong focus on addressing unmet needs in fibromyalgia and expanding its clinical pipeline. The company aims to leverage its unique product offerings and robust marketing strategies to capture a significant share of the market while navigating challenges in prescriber education and competition [33]

Core Insights - Tonix Pharmaceuticals has licensed exclusive worldwide rights to TNX-4900, a selective Sigma-1 receptor antagonist, which has shown analgesic activity in various neuropathic pain models [1][2] - The company aims to advance TNX-4900 through further pharmacokinetic, formulation, and safety studies to support IND-enabling development [4] Company Overview - Tonix Pharmaceuticals is a fully-integrated biotechnology company with marketed products and a pipeline focused on central nervous system disorders, immunology, immuno-oncology, rare diseases, and infectious diseases [5] - The company markets FDA-approved TONMYA, a non-opioid analgesic for fibromyalgia, and has additional treatments for acute migraine [5] Product Development - TNX-4900 was developed using computer-aided and AI-driven approaches, demonstrating robust analgesic efficacy and a favorable safety profile in preclinical models [2][4] - The compound binds to the human Sigma-1 receptor with a nanomolar affinity (Ki = 7.5 nM) and shows over 100-fold selectivity over the Sigma-2 receptor, with an oral bioavailability of approximately 28% [2] Research and Innovation - Foundational research into TNX-4900 represents a significant step towards developing non-opioid solutions for chronic pain, addressing the need for safer pain management options [3] - The compound has produced significant and durable reductions in pain behaviors in preclinical models without evidence of tolerance or motor impairment [4]

Core Insights - Tonix Pharmaceuticals has appointed Irina Ishak as General Counsel, effective December 8, 2025, bringing over 25 years of experience in corporate legal and strategic leadership within the life sciences industry [1][2] - The company is focused on commercializing its marketed products and advancing its pipeline, with Ishak's expertise expected to be a significant asset in these efforts [2][3] Company Overview - Tonix Pharmaceuticals is a fully integrated biotechnology company with marketed products and a development pipeline [4] - The company markets TONMYA™, the first FDA-approved therapy for fibromyalgia in over 15 years, along with treatments for acute migraine [4] - Tonix's development portfolio targets central nervous system disorders, immunology, immuno-oncology, rare diseases, and infectious diseases [4] Recent Developments - The company has recently launched TONMYA™, which is a non-opioid analgesic for fibromyalgia, and is expanding its research into other conditions [3][4] - Tonix is also developing TNX-102 SL for acute stress reaction and major depressive disorder, and has a contract with the U.S. Department of Defense for TNX-4200, a broad-spectrum antiviral agent [4]

Summary of Tonix Pharmaceuticals Holding Conference Call Company Overview - **Company**: Tonix Pharmaceuticals Holding (NasdaqCM: TNXP) - **Focus**: CNS (Central Nervous System), immunology, infectious disease, and rare disease - **Recent Development**: FDA approval of Tonmya for fibromyalgia on August 15, 2025, with a commercial launch expected by the end of November 2025 [2][3] Key Points Product Launch and Financials - **Product**: Tonmya, a sublingual tablet containing cyclobenzaprine, designed for chronic dosing in fibromyalgia treatment [3][4] - **Market Size**: Approximately 10 million American adults suffer from fibromyalgia, with only about 3 million diagnosed and treated [10] - **Financial Position**: As of September 2025, the company reported $190 million in cash, no debt, and a cash runway extending into Q1 2027, fully funding the product launch [3] Market Opportunity - **Unmet Need**: Current FDA-approved treatments for fibromyalgia have high dissatisfaction rates among patients and prescribers, leading to off-label use of opiates [5][10] - **Market Dynamics**: Tonmya enters a market with a 100% share of voice and no counter-promotion, with patent exclusivity until 2034 [5] Product Efficacy and Differentiation - **Efficacy**: Clinical trials showed that Tonmya had a 30% responder rate of 47% compared to 35% for placebo in one study, and 46% versus 27% in another [14] - **Tolerability**: Tonmya demonstrated a favorable side effect profile with minimal adverse events, no significant weight gain, and no cognitive dysfunction reported [15][16] Sales and Marketing Strategy - **Sales Force**: A dedicated team of 90 representatives will target 25,000 healthcare providers who prescribe 70% of fibromyalgia medications [12] - **Omnichannel Approach**: The launch strategy includes unbranded promotion and engagement with prescribers through various channels [12] Pipeline Developments - **Ongoing Studies**: Tonix has several programs in development, including: - TNX-102 SL for acute stress disorder and major depressive disorder [18][19] - Anti-CD40 ligand for autoimmune diseases, with a phase two study planned for kidney transplant recipients [21] - TNX-4800 for Lyme disease prevention, ready for phase two trials [24] - Treatment for Prader-Willi syndrome, with a study expected to start in the second half of 2026 [26] Additional Insights - **Chronic Pain Understanding**: Fibromyalgia is characterized by chronic widespread pain, non-restorative sleep, and fatigue, with a significant portion of patients experiencing polypharmacy [6][7] - **Regulatory Challenges**: The company has faced challenges in PTSD studies but has gathered extensive data that may support future product development for acute stress disorder [30][32] Conclusion - **Strategic Positioning**: Tonix Pharmaceuticals is poised for a successful launch of Tonmya, backed by a strong financial position and a diverse pipeline aimed at addressing significant unmet medical needs in chronic pain and other conditions [28]